Trial Profile

A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dostarlimab (Primary) ; Niraparib (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel; Topotecan
Indications Carcinoma; Endometrial cancer; Ovarian cancer; Sarcoma
Focus Therapeutic Use
Acronyms ROCSAN

08 Mar 2023 Status changed from recruiting to active, no longer recruiting.
08 Jun 2021 Trial design presented at the 57th Annual Meeting of the American Society of Clinical Oncology
29 Jul 2020 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com